



Sustainable Innovation & Health Dividend Fund

TSX SYMBOL: SIH.UN



SUSTAINABLE INNOVATION & HEALTH DIVIDEND FUND IPO Raises \$92 Million

Actively Managed Portfolio of Public and Private Companies that are Driving a Smarter, Healthier and More Sustainable Future

Middlefield Group, on behalf of Sustainable Innovation & Health Dividend Fund (the “Fund”), is pleased to announce that the Fund has completed the issuance of an additional 700,000 units pursuant to the over-allotment option granted to the agents in the Fund’s recently completed initial public offering. **In aggregate, the Fund has raised gross proceeds of \$92,000,000.**

The Fund’s investment objectives are to provide holders of units with:

- (i) stable monthly cash distributions, and
- (ii) enhanced long-term total return through capital appreciation of the Fund’s investment portfolio

through a diversified, actively managed portfolio comprised primarily of dividend paying securities of global technology and healthcare companies, including initially those which the Advisor (as defined below) believes are positioned to benefit long-term from the trends and changing consumer behaviours resulting from the COVID-19 global pandemic (collectively, “Innovative Technology & Healthcare Issuers”). The Advisor believes Innovative Technology & Healthcare Issuers will generate attractive risk-adjusted returns for the Fund as the technology and healthcare sectors have a history of developing long-lasting innovative solutions to address major social and economic challenges. In addition, the portfolio will focus on sustainable technology and healthcare companies with assets the Advisor believes have been developed and operated taking into account environmental, social and governance considerations.

The initial target distribution yield for the Fund is 4% per annum based on the original subscription price (or \$0.03333 per unit per month or \$0.40 per unit per annum). The initial distribution is expected to be declared payable to unitholders of record on October 31, 2020.

Middlefield Capital Corporation (the “Advisor”) provides investment management advice to the Fund. Mr. Paul Sagawa and Dr. Richard Evans act as industry consultants to Middlefield and in such capacity provide ongoing analysis regarding innovative technology & healthcare themes.

The syndicate of agents was co-led by CIBC Capital Markets and RBC Capital Markets, and includes BMO Capital Markets, Scotiabank, TD Securities Inc., Canaccord Genuity Corp., Industrial Alliance Securities, National Bank Financial Inc., Raymond James Ltd., Richardson GMP, Manulife Securities Incorporated, Hampton Securities Limited, Middlefield Capital Corporation, Echelon Wealth Partners Inc. and Mackie Research Capital Corporation.

For further information, please visit our website at www.middlefield.com or contact Nancy Tham or Michael Bury in our Sales and Marketing Department at 1.888.890.1868.



MIDDLEFIELD LIMITED

CALGARY: 812 Memorial Drive NW, Calgary, Alberta T2N 3C8

TORONTO: First Canadian Place, 58th Floor, P.O. Box 192
Toronto, Ontario M5X 1A6

1.888.890.1868 www.middlefield.com invest@middlefield.com

MIDDLEFIELD

CAPITAL CORPORATION

This offering was only made by prospectus. The prospectus contains important detailed information about the securities being offered. Copies of the prospectus may be obtained from your IROC registered financial advisor using the contact information for such advisor. Investors should read the prospectus before making an investment decision.